ScoreWhy is Jenburkt Pharmaceuticals Ltd. ?
1
High Management Efficiency with a high ROE of 18.99%
2
Company has a low Debt to Equity ratio (avg) at 0 times
- PBDIT(Q) Highest at Rs 14.25 cr.
- OPERATING PROFIT TO NET SALES(Q) Highest at 31.93%
- PBT LESS OI(Q) Highest at Rs 13.31 cr.
3
Stock is technically in a Bullish range
- The technical trend has deteriorated from on 18-Jun-26
- Multiple factors for the stock are Bullish like MACD, Bollinger Band and KST
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Jenburkt Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Jenburkt Pharma for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Jenburkt Pharma
-11.69%
-0.34
37.01%
Sensex
-4.95%
-0.39
13.26%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
9.08%
EBIT Growth (5y)
17.95%
EBIT to Interest (avg)
32.51
Debt to EBITDA (avg)
0.11
Net Debt to Equity (avg)
-0.04
Sales to Capital Employed (avg)
1.00
Tax Ratio
25.34%
Dividend Payout Ratio
24.78%
Pledged Shares
0
Institutional Holding
0.12%
ROCE (avg)
35.97%
ROE (avg)
18.99%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
13
Industry P/E
34
Price to Book Value
2.79
EV to EBIT
12.35
EV to EBITDA
11.47
EV to Capital Employed
2.87
EV to Sales
2.97
PEG Ratio
0.75
Dividend Yield
NA
ROCE (Latest)
22.13%
ROE (Latest)
20.70%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend13What is working for the Company
PBDIT(Q)
Highest at Rs 14.25 cr.
OPERATING PROFIT TO NET SALES(Q)
Highest at 31.93%
PBT LESS OI(Q)
Highest at Rs 13.31 cr.
PAT(Q)
Highest at Rs 13.98 cr.
EPS(Q)
Highest at Rs 24.60
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Jenburkt Pharma
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 13.31 cr has Grown at 44.6% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 9.20 CrMOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 13.98 cr has Grown at 72.4% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 8.11 CrMOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 14.25 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Operating Profit Margin - Quarterly
Highest at 31.93%
in the last five quartersMOJO Watch
Company's efficiency has improved
Operating Profit to Sales
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 13.31 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 13.98 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 24.60
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Here's what is not working for Jenburkt Pharma
Non Operating Income - Quarterly
Highest at Rs 4.35 cr
in the last five quartersMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating Income
